LLY vs RMD · P/E 39, rev $22.97B vs P/E 29, rev $5.65B
Eli Lilly and Company (LLY) versus ResMed Inc (RMD) — a side-by-side from cached financials, not a winner call.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David A. Ricks.
ResMed Inc (RMD) is a medical instruments & supplies company listed on US.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Latest reported RMD revenue for 2026-06-30 was $5.65B. Net income was $1.52B. Revenue was up 9.9% from 2025-06-30 to 2026-06-30. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
LLY currently screens at market cap $991.62B and trailing P/E 39.5. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
Not investment advice. Open the LLY and RMD stock pages for the full models.
Not investment advice.